Saturday 17 October 2026 Export BCLI’s income statement to Excel — free account

Brainstorm Cell Therapeutics Inc.

In the quarter to June 2026, EPS fell 2.94%, free cash flow grew 74.4% and total debt rose 1,148.5%, each against the same quarter a year earlier.

0.78 0.02 −2.50%

Follow BCLI

Alert me

Market cap: $7.0M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 40.19%

Capital & Financial Ratios $m

Market Cap 6.99

Revenue —

Net Income (10.52)

Free Cash Flow (4.06)

Net Debt 1.24

Current Ratio 0.03

Debt/Equity (0.11)

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 30.74%

Next Y EPS Growth 10.00%

Next Y revenue growth —

Next 5Y EPS Growth 29.48%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	0	0	0
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	2	0	0	0

	2023	2024	2025	Q'26
Payables	5	6	7	7
ST’ Debt	—	0	1	1
Other	1	1	2	3
	8	9	11	12

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(4)	(1)	(1)	(7)
’24	(3)	(2)	(3)	(1)	(9)
’23	(4)	(7)	(6)	(3)	(20)
’22	(4)	(6)	(5)	(5)	(19)
’21	(9)	(5)	(6)	(6)	(26)
’20	(15)	(6)	(7)	(8)	(35)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(4)	(1)	(1)	(7)
’24	(3)	(2)	(3)	(1)	(9)
’23	(4)	(7)	(6)	(3)	(20)
’22	(4)	(6)	(5)	(5)	(19)
’21	(9)	(5)	(7)	(6)	(27)
’20	(15)	(6)	(7)	(8)	(36)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.19)	(0.35)	—	—	—
’25	(0.45)	(0.34)	(0.19)	(0.20)	(1.11)
’24	(0.75)	(0.60)	(0.51)	(0.51)	(2.31)
’23	(2.10)	(1.95)	(0.45)	(1.65)	(6.00)
’22	(2.25)	(2.85)	(2.85)	(2.10)	(9.90)
’21	(2.85)	(2.55)	(2.25)	(2.55)	(10.19)
’20	(4.80)	(3.75)	(2.10)	(5.55)	(16.04)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	28.50	37.20	43.20	49.65	57.00	41.25	16.35	1.95	1.05	0.52	Analyst estimates 2026–2028 Powerpack
	High	58.05	77.70	80.25	67.50	269.25	122.10	70.50	51.90	11.85	2.37
People
People	Employees	22	24	31	32	40	43	43	29	27	20
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(5)	(5)	(14)	(23)	(32)	(24)	(24)	(17)	(12)	(10)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(5)	(5)	(14)	(23)	(32)	(24)	(24)	(17)	(12)	(10)
	Depreciation	1	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(4.05)	(3.90)	(10.49)	(15.89)	(16.04)	(10.19)	(9.90)	(6.00)	(2.31)	(1.11)
	Cash flow	(4.71)	(1.89)	(9.29)	(7.70)	(17.68)	(10.88)	(7.93)	(7.12)	(1.81)	(0.75)
	Capex	(0.08)	(0.14)	(0.28)	(0.32)	(0.19)	(0.14)	(0.01)	(0.01)	0.00	0.00
	Free cash flow	(4.79)	(2.03)	(9.56)	(8.02)	(17.87)	(11.02)	(7.95)	(7.13)	(1.81)	(0.75)
	Book value	7.95	4.70	3.76	(8.37)	17.81	8.01	(1.24)	(1.69)	(1.55)	(1.08)
	Shares, m	1	1	1	1	2	2	2	3	5	9
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(6)	(2)	(12)	(11)	(35)	(26)	(19)	(20)	(9)	(7)
	Capex	0	0	0	0	0	0	0	0	0	—
	Free cash flow	(6)	(3)	(13)	(12)	(36)	(27)	(19)	(20)	(9)	(7)
Balance, $m
Balance, $m	Working capital	10	4	4	(14)	32	17	(6)	(6)	(9)	(11)
	Total debt	—	—	—	1	3	1	1	—	0	1
	Net debt	(10)	(8)	(7)	1	(39)	(21)	(2)	(1)	0	1
	Shareholders’ equity	10	6	5	(12)	35	19	(3)	(5)	(8)	(10)
Returns, %
Returns, %	ROA	(35.78)	(44.63)	(123.16)	(261.83)	(110.09)	(60.74)	(128.69)	(271.62)	(384.87)	(722.28)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(41.46)	(62.76)	(256.02)	645.29	(273.75)	(89.25)	(297.38)	436.73	184.17	116.14

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CALC CalciMedica Inc.	$7.4M	— (loss-making)	—	—	n/m	+31.42% (above 0%: growing)	0.00%	0.00%	Compare
XCUR Exicure, Inc.	$7.3M	— (loss-making)	— (loss-making)	−80.51% (below 0%: shrinking)	n/m	+65.38% (above 0%: growing)	100.00%	0.00%	Compare
SKYE Skye Bioscience, Inc.	$7.0M	— (loss-making)	—	−34.71% (below 0%: shrinking)	n/m	+34.84% (above 0%: growing)	72.71%	0.00%	Compare
BCLI Brainstorm Cell Therapeutics Inc.	$7.0M	— (loss-making)	—	—	n/m	+74.44% (above 0%: growing)	0.00%	0.00%
CLGN CollPlant Biotechnologies Ltd. Sponsored ADR	$7.0M	— (loss-making)	— (loss-making)	−39.66% (below 0%: shrinking)	n/m	+5.08% (above 0%: growing)	(422.22%)	(2,437.96%)	Compare
NIKI Niki BioSolutions, Inc.	$6.9M	— (loss-making)	31.9×	−32.36% (below 0%: shrinking)	+69.51% (above 0%: growing)	+58.14% (above 0%: growing)	(154.22%)	0.00%	Compare
AIM AIM ImmunoTech Inc.	$6.8M	— (loss-making)	— (loss-making)	+4.00% (above 0%: growing)	n/m	−167.46% (below 0%: shrinking)	80.77%	(13,511.54%)	Compare
SYBX Synlogic, Inc.	$6.7M	— (loss-making)	— (loss-making)	−95.40% (below 0%: shrinking)	n/m	−277.87% (below 0%: shrinking)	100.00%	0.00%	Compare
FBLG FibroBiologics Inc.	$6.7M	— (loss-making)	—	—	n/m	+21.59% (above 0%: growing)	—	0.00%	Compare
Median of peers	$6.9M	—	—	−37.18%	—	+26.51%	72.71%	0.00%

All 614 Biotechnology stocks →